High materiality7/10
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
URGN price target raised to $44 from $18 at Goldman Sachs.
- URGN target raised to $44 by Goldman Sachs.
Key facts
- 01
Target: $44
- 02
Posted price: $39.8
- 03
Analyst firm: Goldman Sachs
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.